Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-04-24
2007-04-24
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S239100, C424S247100, C436S008000, C436S018000, C514S002600
Reexamination Certificate
active
10250486
ABSTRACT:
Use of botulin toxin to obtain a product intended to be administered intramuscular with lissive effect in treating articular pathologies, particularly coxarthrosis, or arthrosis of the hip, epicondylitis of the elbow and rotator muscle cap pathology of the shoulder.
REFERENCES:
patent: 6063768 (2000-05-01), First
patent: 6395277 (2002-05-01), Graham
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6869610 (2005-03-01), Aoki et al.
patent: 7091176 (2006-08-01), Aoki et al.
patent: 2002/0176872 (2002-11-01), Aoki et al.
patent: 93 05800 (1993-04-01), None
patent: 95 17904 (1995-07-01), None
patent: 0015245 (2000-03-01), None
Robertsson et al (Journal of Arthroplasty, Oct. 1995, vol. 10. No. 5, p. 632-635).
Williams & Wilkins, Stedman's Medical Dictionary, 26thEdition, Illustrated in Color, 1995, p. 988.
Gracies et al.,Neurologist2000, 6(2), “Botulinum Toxin Therapy”, pp. 98-115.
Kessler et al.,Neurologist Toxicology1997, 18(3), “Botulinium Toxin: From Poison to Remedy”, pp. 761-770.
Montecucco et al.,Mol Microbiol, 1994, 13(1), Mechanism of Action of Tetanus and Botulinum Neurotoxins, pp. 1-8.
Polo et al.,Mov Disord1994, 9 (suppl. 1), “Botulinum Toxin A and Rigidity”, p. 84.
Boyd et al.,European Journal of Neurology1999, 6 (suppl. 4), “Objective Measurement of Clinical Findings in the use of Botulinum Toxin Type A for the Management of Children With Cerebral Palsy”, pp. S23-S35.
Boyd et al.,European Journal of Neurology1999, 6 (suppl. 4), Medium-Term Response Characterisation and Risk Factor Analysis of Botulinum Toxin Type A in the Management of Spasticity in Children With Cerebral Palsy, pp. S37-S45.
Boyd et al.,Dev Med Child NeurolAug. 1998, 40 (suppl. 78), “Session I: Botox”, pp. 28-29.
G. Jenkins and W. Hartung, The Chemistry of Organic Medicinal Products, Moscow, p. 420 (1949).
BOTOX© product entry; “Neuromuscular Agents”, 2000 Mims Annual, pp. 5-433 to 5-434.
Gasser et al.; “Botulinum Toxin a in Orthopaedic Surgery”, The Lancet, Sep. 21, 1991; vol. 338 (8769); p. 761.
Morre et al.; “Treatment of Chronic Tennis Elbow With Botulinum Toxin”;The LancetJun. 14, 1997; vol. 349 (9067); p. 1746.
Placzek et al.; “Therapy for Chronic Radial Epicondylitis With Botulinum Toxin A - A Therapy Trial with a 2-Year-Follow-Up”, Z Orthop Ihre Grenzgeb; Nov.-Dec. 2004; 142(6); p. 701-705 (Reference with Abstract in English).
S.M. Wong et al., “Treatment of Lateral Epicondylitis With Botulinum Toxin. A Randomized, Double-Blind, Placebo-Controlled Trial”, Summaries for Patients; Annals of Internal Medicine; Dec. 6, 2005; 143(II); pp. 148, 793-797, and W-161.
Abstract of AU 15162/95, published Jul. 17, 1995.
Abstract of AU 25664/92, published Apr. 27, 1993.
Marchini Corrado
Pinat Fabiano
Pinat Fabio
Zecchini Francesca
Ford Vanessa L.
Minnifield Nita
Societe de Conseils de Recherches et d'Applications Scientifique
Stevens Davis Miller & Mosher LLP
LandOfFree
Use of botuline toxin to obtain a product to be used in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of botuline toxin to obtain a product to be used in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of botuline toxin to obtain a product to be used in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784326